Exagen Inc.
NASDAQ:XGNMedical - Diagnostics & Research
+$0.16 today
- Market cap
- $99.50M
- Beta
- 2.02
- P/E (TTM)
- -5.2
- EPS (TTM)
- -$0.85
Volume 0.47M
Average 0.39M
XGN Net Income
Bottom-line profit, the starting point for calculating cash from operations.
Exagen Inc.NASDAQ: XGN
Net Income · Q1 FY2026 · quarter ended Mar 2026
Net income grows, but more slowly than its trailing trend
Q1 FY2026 net income of $3.97M (cash outflow) rose 5.7% year over year, behind the +30.0% change in trailing-twelve-month net income. Sequentially, it fell 15.1% from the prior quarter. Over 3 fiscal years it compounded at -25.1% a year.
Context
- Net income amounted to 30.0% of revenue in FY2025, up 2.8 pp from a year earlier.
- Net income grew in size in 1 of the last 3 fiscal years.
What to watch
Whether net income reaches the consensus estimate from 6 analysts of -$15.58M (-21.9%) for the fiscal year ending Dec 2026, a slowdown from the +32.0% reported in FY2025.
Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$3.97M-15.1% QoQ
- Last fiscal yearDec 2025
- -$19.95M+32.0% YoY
- LTMMar 2026
- -$20.17M+30.0% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +5.7% | +7.2% | +1.4 pp |
| 1 year | +32.0% | -21.9% | -53.9 pp |
| 3-year CAGR | -25.1% | -24.0% | +1.0 pp |
| 5-year CAGR | -34.7% | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the cash flow
- Latest · FY2025
- (19.95M) USD
- Year-over-year change
- -32.0%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (19.95M) | -32.0% |
| FY2024 | 2024-12-31 | (15.12M) | +36.2% |
| FY2023 | 2023-12-31 | (23.69M) | +50.0% |
| FY2022 | 2022-12-31 | (47.39M) | -76.5% |
| FY2021 | 2021-12-31 | (26.85M) | — |
Net Income vs competitors
How XGN compares with its peers on the latest reported figures
- XGN's LTM Mar 2026 net income of $20.17M is the 9th largest of the 11 companies compared; the peer median is $35.67M.
- Its year-over-year change of +30.0% is the 3rd highest of 10, against a peer median of -24.6%.
- Net income amounts to 29.5% of revenue for XGN, versus a peer median of 43.9%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $239.55M | +441.4% | — | 110.0% | |
BIOABioAge Labs, Inc. | LTM Mar 2026 | $89.93M | +26.6% | +26.6% | 871.8% |
| LTM Mar 2026 | $69.66M | -46.5% | -9.3% | 832.6% | |
| LTM Jun 2026 | $51.88M | -50.1% | -9.2% | 6.8% | |
| LTM Mar 2026 | $37.25M | -24.6% | -23.6% | 46.8% | |
| LTM Mar 2026 | $34.09M | — | -30.8% | 25.2% | |
| LTM Mar 2026 | $23.67M | +103.8% | +50.6% | 22.0% | |
| LTM Mar 2026 | $21.68M | -14.5% | +5.8% | 69.5% | |
| LTM Mar 2026 | $20.17M | +30.0% | -25.1% | 29.5% | |
| LTM Mar 2026 | $17.17M | -26.3% | -28.6% | 41.1% | |
| FY2025 | $14.41M | -41.7% | -27.6% | 13.4% | |
| Peer median (excluding XGN) | $35.67M | -24.6% | -9.3% | 43.9% | |
Competitors are the stored peer set for XGN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (26.85M) | (47.39M) | (23.69M) | (15.12M) | (19.95M) |
| Depreciation & Amortization | 948K | 1.56M | 2.17M | 1.72M | 2.12M |
| Deferred Income Tax | 148K | (306K) | 0 | 0 | 0 |
| Stock-Based Compensation | 4.73M | 4.7M | 3.62M | 1.76M | 2.16M |
| Change in Working Capital | (61K) | 1.67M | 325K | (3.08M) | (1.98M) |
| Accounts Receivables | (744K) | 3.58M | (474K) | (1.28M) | (3.02M) |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | (655K) | 901K | 67K | 308K | 42K |
| Other Working Capital | 1.34M | (2.81M) | 732K | (2.1M) | 997K |
| Other Non-Cash Items | 819K | 7.62M | 3.12M | 1.43M | 4.03M |
| Operating Cash Flow | (20.27M) | (32.14M) | (14.46M) | (13.28M) | (13.63M) |
| Capital Expenditures | (2.37M) | (4.32M) | (828K) | (515K) | (641K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 15K |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | (50K) | 0 | 24K | 0 | 0 |
| Investing Cash Flow | (2.42M) | (4.32M) | (804K) | (515K) | (626K) |
| Debt Repayment | (525K) | (696K) | (10.94M) | (861K) | 2.01M |
| Common Stock Issued | 69.14M | 446K | 306K | 198K | 22.42M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (3.94M) | (239K) | 0 | 0 | 0 |
| Financing Cash Flow | 64.68M | (489K) | (10.63M) | (663K) | 24.44M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 41.99M | (36.95M) | (25.9M) | (14.46M) | 10.18M |
| Free Cash Flow | (22.64M) | (36.46M) | (15.29M) | (13.79M) | (14.27M) |
Exagen Inc.
NASDAQ:XGN
Intrinsic Alpha fair value
Locked
Current Price
$3.90
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.